Literature DB >> 10924969

Postoperative brachytherapy alone for T1-2 N0 squamous cell carcinomas of the oral tongue and floor of mouth with close or positive margins.

M Lapeyre1, S Hoffstetter, D Peiffert, S Guérif, F Maire, G Dolivet, B Toussaint, A Mundt, J F Chassagne, C Simon, P Bey.   

Abstract

PURPOSE: To evaluate the efficacy of postoperative brachytherapy alone (brachy) for Stage T1-2 squamous cell carcinomas (SCC) of the floor of mouth (FM) and the oral tongue (OT) with close or positive margins. METHODS AND MATERIALS: Between 1979 and 1993, 36 patients with T1-2 N0 (24 T1, 12 T2) OT (19), and FOM (17) SCC with close or positive margins following surgery underwent postoperative brachy. Mean patient age was 56 years (range 37-81) and sex ratio was 3.5:1 male:female. Mean surgery to brachy interval was 36 days (range 16-68). The technique used was interstitial Iridium-192 ((192)Ir) brachytherapy with plastic tubes and manual afterloading. Mean total dose was 60 Gy (range 50-67.4) at a mean dose rate of 0.64 Gy/h (range 0.32-0.94). Mean patient follow-up was 80 months.
RESULTS: The 5-year actuarial overall and cause-specific survivals of the entire group were 75% and 85%, respectively. The local control was 88.5% at 2 years, with a plateau apparent after 23 months. Of the 4 local relapses, 2 were salvaged with surgery and external beam radiotherapy (EBR). No tumor or treatment factors, including tumor size, margin status, disease site, or radiation dose, were correlated with local control. The 2 head and neck second primaries underwent curative treatment on nonirradiated tissue. One patient developed a grade 3 sequelae (bone and soft tissue necrosis). Grade 2-3 chronic sequelae were seen in 7 of 17 and 3 of 19 FOM and OT tumors, respectively (p = 0.09).
CONCLUSION: Postoperative brachy is a promising approach in T1-2 N0 OT and FOM SCC with close or positive margins. This approach is associated with high rate of locoregional control and low risk of chronic sequelae, obviates major surgery, avoids potential sequelae of EBR (xerostomia, dysgueusia, fibrosis), and avoids treatment of second head and neck primary on nonirradiated tissues.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10924969     DOI: 10.1016/s0360-3016(00)00538-1

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  6 in total

1.  Adjuvant brachytherapy for oral squamous cell carcinomas: a single-center experience comparing low-dose and pulsed-dose-rate techniques.

Authors:  Pierre Mattei; Emilien Chabrillac; Bastien Cabarrou; Agnès Dupret-Bories; Sébastien Vergez; Jérôme Sarini; Raphaël Lopez; Lucie Piram; Thomas Brun; Anouchka Modesto
Journal:  Strahlenther Onkol       Date:  2021-11-16       Impact factor: 3.621

2.  Paired box 5 methylation detection by droplet digital PCR for ultra-sensitive deep surgical margins analysis of head and neck squamous cell carcinoma.

Authors:  Masamichi Hayashi; Rafael Guerrero-Preston; David Sidransky; Wayne M Koch
Journal:  Cancer Prev Res (Phila)       Date:  2015-08-24

3.  Prognostic value of clinicopathological parameters and outcome in 484 patients with oral squamous cell carcinoma: microvascular invasion (V+) is an independent prognostic factor for OSCC.

Authors:  M Grimm
Journal:  Clin Transl Oncol       Date:  2012-07-19       Impact factor: 3.405

Review 4.  Is There Still a Place for Brachytherapy in the Modern Treatment of Early-Stage Oral Cancer?

Authors:  Luboš Tuček; Milan Vošmik; Jiří Petera
Journal:  Cancers (Basel)       Date:  2022-01-03       Impact factor: 6.639

5.  Results of sole postoperative interstitial, high-dose-rate brachytherapy of T1-2 tongue tumours.

Authors:  Zoltán Takácsi-Nagy; Örs Ferenczi; Tibor Major; Hironori Akiyama; Georgina Fröhlich; Ferenc Oberna; Mónika Révész; Márton Poósz; Csaba Polgár
Journal:  Strahlenther Onkol       Date:  2022-02-14       Impact factor: 4.033

6.  A multicenter prospective phase II study of postoperative hypofractionated stereotactic body radiotherapy (SBRT) in the treatment of early-stage oropharyngeal and oral cavity cancers with high risk margins: the STEREO POSTOP GORTEC 2017-03 trial.

Authors:  Julian Biau; Emilie Thivat; Corinne Millardet; Nicolas Saroul; Nathalie Pham-Dang; Ioana Molnar; Bruno Pereira; Xavier Durando; Jean Bourhis; Michel Lapeyre
Journal:  BMC Cancer       Date:  2020-08-05       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.